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BACKGROUND
Advanced glycation-end products (AGEs) are a het-
erogeneous group of fluorescent and non-fluorescent
compounds implicated in the pathogenesis of the
micro- and macro-vascular complications of diabe-
tes, and in renal disease and atherosclerosis in the
non-diabetic population. AGEs can form in short- and
long-lived proteins such as albumin, immunoglobu-
lins, lipoproteins, skin collagen, ocular, renal and
vascular tissues (1). AGEs may be both a cause and
effect of inflammation, oxidative stress and dyslipo-
proteinemia (2, 3). Recent animal and human studies
show benefit of AGE-inhibitors and AGE-breakers
in ameliorating renal and cardiovascular damage
(4, 5). Therefore AGE levels may have a role in the
identification of Type 1 diabetic patients at high risk
for complications and also provide a tool for moni-
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toring therapeutic interventions.
Circulating low molecular weight (10 kDa) AGEs
(LMW-AGEs or AGE-peptides) can be measured by
relatively simple non-specific fluorescence spectros-
copy, which may otherwise only be detected by so-
phisticated and laborious assays (6). Given the cur-
rent lack of biochemical characterization of these
compounds, an alternative less specific name is low
molecular weight fluorophores (LMW-F). Relative
to healthy subjects, serum LMW-F levels have been
reported to be elevated in diabetes (7-9), in (diabetic
and non-diabetic) renal failure (10) and to be low-
ered by hemodialysis (11). In a large cross-sectional
study of Type 2 diabetes patients LMW-AGEs were
inversely related to renal function and to hemoglo-
bin levels (independent of renal function) (8). Us-
ing a fluorescence spectroscopy assay with potential
clinical utility, we previously reported that plasma
LMW-F levels were elevated in patients with Type 1
diabetes (T1DM) and vascular complications, and
that levels did not differ between complication-free
T1DM patients and healthy non-diabetic subjects
(12). In this cross-sectional study LMW-F levels
were correlated with renal function, but not with age,
diabetes duration, body habitus, smoking, glycemia,
lipid levels or arterial elasticity (12).
We now present the behavior over time of LMW-F
levels in T1DM patients, and their relationships with
renal and vascular health, and measures of glyce-
mia, inflammation and oxidative damage.
METHODS
Subject characterization : The study was approved
by the St Vincent’s Hospital Human Research Eth-
ics Committee and each subject gave written in-
formed consent. Thirty-seven patients with T1DM
(13 with and 24 without complications) with (mean
SD) diabetes duration of 2113 years from the
St. Vincent’s diabetes clinics volunteered for the
study. Patients attended at least twice at an inter-
val of 12-60 months ; long enough for changes in
glycemia to be reflected by the concurrent HbA1c
level. We compared results with data obtained (on
one occasion) from 112 healthy control subjects.
These control subjects did not have clinically evi-
dent macrovascular disease, hypertension, diabe-
tes, renal disease or dyslipidemia requiring drug
treatment. They were not taking any medications
(other than the oral contraceptive pill). No subject
was taking antioxidant vitamin supplements. Smok-
ers were not excluded from the study.
Blood pressure and arterial elasticity were meas-
ured in fasted supine subjects by pulse-wave analysis
(HDI Inc, Egan, MN) as previously described (13),
including measures of vascular elasticity and sys-
temic vascular resistance (SVR). Venous blood was
taken after an overnight fast and a single void urine
sample collected. Routine clinical chemistry was
performed by the St.Vincent’s Hospital Pathology
Department. For research analyses plasma (1 mM
EDTA) and serum were prepared (2000 g, 15 min,
4) and stored (-80) until LMW-F, cystatin C
and measures of inflammation (high sensitivity C-
reactive protein, (hs-CRP) and ESR) and oxidative
damage (Oxidized LDL, (OxLDL)) were assayed.
Levels of LMW-fluorophores in (first-thaw) plasma
were determined in duplicate by fluorescence spec-
troscopy as described (8), with intra- and inter-assay
coefficients of variation (CV) of 5.2% and 7.3% re-
spectively. In preliminary studies there were no sta-
tistically significant differences between LMW-F in
serum and EDTA plasma from the same subjects,
and LMW-fluorescence was stable through two, but
not three, freeze-thaw cycles. For the analysis of
yearly changes a subset of subjects (n=37) with one
year or more between-visit intervals were studied
(see below). Creatinine clearance was calculated
using the Cockroft-Gault formula (14, 15). Nor-
mal range is defined as 90 - 150 ml/min. Cystatin
C was measured in serum by nephelometry using
Dade Boehring, Germany instrument. The refer-
ence interval is 0.53 - 0.95 mg/l. Intra- and interas-
say CV’s were 3.3%. Oxidative stress : Oxidized
LDL was measured in serum by ELISA (Mercodia
AB, Uppsala, Sweden). All intra- and inter-assay
CVs were6.3% and12.0% respectively.
To control for the potential influence of the dif-
ferent time intervals at which patients were stud-
ied and reduce variance, all changes were normal-
ized, using the formula below, as the percentage
change per annum, with initial visit values being
taken as 100%. Thus, a positive or negative percent
change at last visit reflects both change in magni-
tude and direction.
Percent change=100 (
YearsLast visit-YearsFirst visit)
YearsFirst visit
Years = time between 1st and last assessment in years
Data were analyzed using Statistica for Windows
(StatSoft, Inc. (2007) Tulsa, OK. STATISTICA (data
analysis software system), version 8.0 www.statsoft.
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com). Non-normally distributed variables : hsCRP,
triglycerides (TG), urinary albumin and albumin
to creatinine ratio (ACR) values, were transformed
logarithmically. Differences between diabetic and
control subjects were analyzed using Student-t -test
and between control subjects and diabetic patients
subdivided into those with and without complica-
tions (CX[+] and CX[-] respectively) - using one way
analysis of variance (ANOVA). For correlation analy-
ses Pearson’s correlation coefficient was calculated
and multiple regression analysis done. Statistical
significance was taken at p0.05.
RESULTS
Subject characteristics are reported in Table 1.
Thirty-seven subjects (20 women and 17 men, 13
with and 24 without diabetes complications) with
T1DM studied at an interval of at least 1 year were
evaluated. MeanSD follow-up time was 3315
months, with a range of 12 - 60 months. Data are
given for controls (at baseline) and for all diabetic
subjects at their first and final visit. There was no
statistically significant change in any clinical or bio-
chemical parameter analyzed over the study dura-
tion.
Longitudinal measures of LMW-F in diabetes and its
complications. The baseline characteristics of the
group studied longitudinally did not differ from that
of the whole larger diabetic group (n=148) in the
previously reported cross-sectional study (12), and
also did not differ significantly from those diabetic
subjects not restudied (data not shown). Relative to
healthy controls, plasma LMW-F were increased in
patients with T1DM at the initial but not at the final
visit (5.41.9 AU/ml at the initial visit and 4.5
1.8 AU/ml at the final visit vs. 3.82.1 AU/ml ; p=
0.0001 and p=0.06 respectively). Levels of LMW-F
were significantly higher at the beginning of the
study relative to those at the final visit (5.41.9
AU/ml vs. 4.51.8 AU/ml, p=0.02). In 19 subjects
in whom LMW-F levels were measured more than
twice, mean LMW-F levels between first and final
visit correlated with values obtained at the last visit
(r=0.79 ; p0.00001). However, when data from the
first visit were compared with mean levels obtained
at all other visits (including the last one) the statis-
tical significance disappeared (5.41.9 AU/ml vs.
4.91.8 AU/ml, p=0.24).
Table 1. Clinical characteristics of Control and Type 1 diabetic (T1DM) subjects. Data are meanSEM.
Control
subjects
Type 1 DM
First visit
Type 1 DM
Last visit
n (M/F) 112 (52/60) 37 (17/20) 37 (17/20)
Age (years) 3712 3414 3714
BMI (kg/m2) 25.04.1 25.64.4 26.04.9
SBP (mmHg) 12013 12813* 12815*
DBP (mmHg) 6810 7310* 7310*
MAP (mmHg) 8712 9411* 9312*
Pulse pressure (mmHg) 528 5714* 5510
LAE (ml/mmHg10) 17.64.9 16.44.6 16.96.0
SAE (ml/mmHg100) 8.33.4 6.12.7* 6.93.5*
SVR (dyneseccm-5) 1246230 1336268 1296270
Fasting serum glucose (mmol/l) 4.90.5 11.74.6* 11.55.6*
HbA1c (%) 5.10.3 8.11.5* 8.11.9*
Total Cholesterol (mmol/l) 5.11.0 5.01.0 4.61.0*
Triglycerides (mmol/l) 1.110.68 1.160.82 0.970.56
HDL-Cholesterol (mmol/l) 1.520.38 1.490.53 1.360.33
OxLDL/LDL ratio (U/mmol) 33.212.3 35.56.9 33.813.9
Hemoglobin (g/l) 14016 13720 13715
ESR (mm/h) 14.347.9 9.69.2 12.411.3
Urinary Albumin/Creatinine (mg/mmol) 0.81.2 9.921.7* 19.869.7*
Serum BUN (mg/l) 4.91.2 6.22.3* 7.23.9*
Cystatin C (mg/l) 0.780.10 0.890.36 1.030.58*
GFR (ml/s) 1.750.54 1.710.53 1.951.92
Hs-CRP (mg/l) 1.72.2 2.42.5 2.72.6*
LMW-F (AU/ml) 3.82.1 5.41.9* 4.51.8*
Current smokers (n/%) 15/13 7/19 10/27*
Lipid lowering drugs (n/%) 0 22 30
*) p0.04 vs. Controls
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There was no statistically significant difference
between LMW-F levels between women and men at
the beginning (meanSD : females 5.92.2 AU/
ml vs. males 4.8  1.3 AU/ml ; p=0.08) or end of
the study (meanSD : females 5.02.0 AU/ml vs.
males 3.91.3 AU/ml ; p=0.07). However in men
LMW-F levels decreased significantly during the
study (4.81.3 AU/ml at the initial visit vs. 3.9
1.3 AU/ml at the final visit ; p=0.03) whereas lev-
els in women did not change significantly (5.9 
2.2 AU/ml at study beginning vs. 5.02.0 AU/ml
at the end ; p=0.18). There was no statistically sig-
nificant difference between LMW-F levels in sub-
jects stratified by diabetes complication status. In
the complication-free group baseline LMW-F levels
were 5.62.0 AU/ml and 4.51.3 AU/ml at the
end of the study. In the diabetic group with compli-
cations baseline LMW-F levels were 5.11.9 AU/
ml and 4.6  2.5 AU/ml at the end of the study.
This change did not reach statistical significance in
either group. The time intervals at which subjects
were studied did not correlate with differences be-
tween LMW-F levels.
In univariate analysis of cross-sectional data, initial
LMW-F levels correlated with baseline hs-CRP (r=
0.51 ; p=0.005) values, with ACR (r=0.48 ; p=0.03),
and with calculated GFR levels (r=0.50 ; p=0.007),
as previously reported In the larger diabetes group
(12). Baseline LMW-F levels predicted final visit
hs-CRP (r=0.57 ; p=0.002) and OxLDL/LDL ratio
(r=0.69 ; p=0.001) (Figure 1). In this respect they
were better predictors than HbA1c and TG levels
as neither baseline level correlated with final visit
hs-CRP or OxLDL/LDL ratio. Final LMW-F corre-
lated with : final mean arterial pressure (also sys-
tolic and diastolic blood pressure) (r=0.52 ; p=0.002),
systemic vascular resistance (r=0.38 ; p=0.03) se-
rum creatinine (r=0.45 ; p=0.006), BUN (r=0.48 ;
p=0.004), cystatin C (r=0.62 ; p=0.002), and urinary
ACR (r=0.69 ; p=0.0001), serum billirubin (an antioxi-
dant) (r=-0.51 ; p=0.04) and ESR (r=0.66 ; p=0.0001).
Serum BUN and ACR values at baseline correlated
significantly with end-point LMW-F (r=0.38 ; p=0.03
and r=0.46 ; p=0.03 respectively). There was a sig-
nificant negative correlation between initial hemo-
globin levels and final LMW-F levels (r=-0.54 ; p=
0.009).
In multivariate analysis after adjustment for gen-
der, age, diabetes complications, glycemic control,
renal function (GFR), lipids (TG, HDL-C, non-HDL-
C) and inflammation the strongest predictors of
LMW-F levels at the initial visit were gender (p=
0.006), renal function (p=0.002) and TG levels (p=
0.03). In the same model applied at the final visit the
only statistically significant predictor of LMW-F lev-
els was renal function (p=0.002). Similarly when the
model was applied to combined data from baseline
and final visits the significant predictors of LMW-F
levels were diabetes complication status (p=0.04)
and renal function (ACR) (p=0.0002).
In control subjects significant correlations between
LMW-F and albuminuria (but not ACR) (r=0.22 ; p=
0.03) and TG (r=0.21 ; p=0.03) were noted. There
was no significant difference between LMW-F lev-
els in males and females in the control group (3.9
0.4 vs. 3.80.2 AU/ml ; p0.05 respectively). In
multivariate analysis after the adjustment for gender,
age, glycemia, renal function, lipids and inflamma-
tion the only significant LMW-F predictor in healthy
subjects was TG level (p=0.007).
In T1DM subjects, the annual percentage change
in LMW-F between visits correlated with the yearly
change in BMI (r=0.43 ; p=0.02), systolic blood pres-
sure (r=0.54 ; p=0.004), pulse pressure (r=0.54 ; p=
0.004), systemic vascular resistance (SVR) (r=0.39 ;
p=0.04), BUN (r=0.38 ; p=0.03), HbA1c (r=0.38 ; p=
A B C
Figure 1. Baseline LMW-F levels correlated significantly with inflammation (hs-CRP) (panel A) and OxLDL/LDL ratio (panel B)
at the end of the study. Baseline hemoglobin level correlated significantly with LMW-F levels at the end of the study (panel C).
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0.04) and hemoglobin (r=0.65 ; p=0.005) (Figure 2).
Mean HbA1c levels measured during the study cor-
related with SVR yearly percentage changes (r=
0.44 ; p=0.03). Similarly, mean TG levels correlated
with hs-CRP yearly percentage changes (r=0.56 ; p=
0.009). Annual percentage changes in TG levels cor-
related with the yearly changes in hs-CRP levels (r=
0.51 ; p=0.02) and the OxLDL/LDL ratio (r=-0.67 ;
p=0.02).
DISCUSSION
We report results of a longitudinal study of plasma
LMW-F levels measured by a relatively simple tech-
nique in Type 1 diabetic patients. Relative to healthy
subjects LMW-F levels were increased in diabetes
regardless of complication status. There was a sig-
nificant decrease in LMW-F levels over the study
period in the diabetic group as a whole, however not
as a result of amelioration of renal function, as se-
rum creatinine, BUN, GFR and ACR did not change
significantly. Also, when individual changes were
expressed as percentage change per annum they
correlated with changes in BMI, HbA1c, vascular
health, as measured by pulse-wave analysis, BUN
and hemoglobin. Baseline LMW-F levels correlated
with inflammation and renal function parameters
and were predictive of oxidation stress and inflam-
mation. In multivariate analysis LMW-F levels were
determined by renal function and lipids.
In a cross-sectional analysis LMW-F were related
to inflammation (hs-CRP), renal function (ACR, cal-
culated GFR, serum creatinine, cystatin C), vascu-
lar status (blood pressure, systemic vascular resis-
tance). No associations between age, diabetes du-
ration, body habitus, HbA1c or oxidative stress and
LMW-F levels were noted. These findings are simi-
lar to large cross-sectional studies of subjects with
Type 2 diabetes (8) and a mixed group of subjects
with Type 1 and Type 2 diabetes, in which levels in
T1DM (20% of the group) were not reported sepa-
rately (7). In both studies levels of LMW-AGEs (as
these compounds are referred to in these reports)
were significantly higher in patients with diabetes
than in non-diabetic subjects. Limited data are avail-
able regarding LMW-F levels in T1DM. Using fluo-
rescence spectroscopy Galler, et al. found increased
levels of fluorescent AGEs in a pediatric group with
T1DM, which were positively correlated with HbA1c
and TG levels (9). We previously reported a cross-
sectional analysis of 148 T1DM patients in which
LMW-F levels correlated with serum creatinine and
BUN, and creatinine clearance, and these relation-
ships were statistically significant even within the
normal range of renal function. In addition, LMW-F
A
B
C
D
Figure 2. Percentage change of LMW-F between first and last
visit normalized per year correlated significantly with values of
the yearly change of pulse pressure (panel A), systemic vascu-
lar resistance (panel B), BUN (panel C) and HbA1c (panel D).
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levels correlated with urinary ACR. There were no
statistically significant relationships between LMW-F
and diabetes duration, age or HbA1c in this cross-
sectional study (12), as in this present study. Here
in a longitudinal study we showed a correlation be-
tween annual percentage changes of HbA1c and
LMW-F levels. In multivariate analysis TG were the
third strongest predictor (after renal function and
gender) of LMW-F levels. Blood samples were fast-
ing, which would reduce the potential influence of
dietary AGEs (16). The finding of a significant as-
sociation between LMW-F and lipids in our study
supports the notion that AGEs can form within and
be derived from lipoproteins - Advanced Lipoxida-
tion End products (ALEs) (3, 17).
T1DM with microvascular complications was as-
sociated with higher LMW-F (in our earlier larger
cross-sectional study (12), and in keeping, in this
current study renal function (expressed as GFR or
ACR) was the strongest predictor of LMW-F levels.
Our results support previous research that LMW-F
levels are related to renal function (8, 12). In addi-
tion, studies by others investigating low- and high-
molecular weight AGEs demonstrate elevated lev-
els in renal failure (10, 18) with a reduction by high-
flux hemodialysis (19, 20). It is uncertain if the ele-
vated level of LMW-F or other AGEs in renal dis-
ease relates to impaired removal, increased produc-
tion, or both. ACE inhibitors, a common treatment
for increased urinary albumin loss and for hyper-
tension in diabetes can lower AGEs (21). However
in this present study and in our earlier larger cross-
sectional series, LMW-F levels did not differ be-
tween diabetic subjects taking ACE-inhibitors or an-
giotensin receptor blocking agents and those not
on these medications (data not shown). We found
a strong negative correlation between initial hemo-
globin levels and final LMW-F. A similar observa-
tion was previously reported by Thomas, et al. (8).
They reported that anemic patients with T2DM had
higher levels of LMW-F than non-anemic T2DM pa-
tients. In our study no patients were anemic ; how-
ever we did find significant correlations between
hemoglobin and LMW-F levels, and also between
the annual changes of both measures. This may re-
flect a more subtle effect of renal dysfunction on
hemoglobin levels. It may also reflect that reduced
tissue oxygenation contributes to AGE formation, or
it may reflect increased oxidative stress as the re-
sult of disturbed protein metabolism or inflamma-
tion, or both.
In this present study age and diabetes duration
were not related to LMW-F levels. In contrast Sharp,
et al. found that age correlated positively with LMW-
AGEs levels in both their older control and (pre-
dominantly T2DM) diabetic groups (7). This may
be related to age-related renal function decline. A
correlation between age, diabetes duration and fluo-
rescent AGEs was observed in children and adoles-
cents with T1DM (9). By dividing subjects into two
age subgroups (9-13 and 13-16 years) the authors
showed a 15% increase in LMW-AGE levels. This
may reflect a pubertal effect, and the relevance of
this finding to our non-pediatric population is un-
clear.
Circulating AGE levels have been correlated with
endothelial dysfunction measured by flow-mediated
dilatation (FMD) (22). In our studies final circulat-
ing LMW-F levels were related to measures of vas-
cular health (mean arterial pressure, systolic and
diastolic blood pressure and SVR, but no such cor-
relations were observed at the initial visit. Changes
in LMW-F levels, expressed as percentage per year,
correlated with similarly expressed changes in sys-
tolic blood pressure, pulse pressure and SVR. In this
regard LMW-F was a comparable vascular health
predictor to HbA1c.
AGE formation may be promoted by inflamma-
tion, and conversely AGEs can induce inflammation,
including vascular endothelial cell adhesion mole-
cule expression (23, 24). In keeping, we noted sig-
nificant correlations between baseline LMW-F and
ESR and CRP levels. We also noted a correlation be-
tween mean and yearly percent changes of TG lev-
els with percent changes per year of hs-CRP levels.
The strength of these correlations was comparable
with that between LMW-F and hs-CRP but the sta-
tistical significance in each case was lower than that
between LMW-F and hs-CRP. Similarly AGE for-
mation may induce and be promoted by oxidative
stress (17, 25) and we identified a relationship be-
tween initial LMW-F and final OxLDL/LDL ratio.
The changes in the OxLDL/LDL ratio also corre-
lated significantly with changes in TG levels, but the
statistical strength of this correlation was lower than
that between LMW-F and the OxLDL/LDL ratio.
In conclusion, our results suggest that levels of
LMW-F rise early with a decline in renal function,
at a time when an effective therapeutic intervention
could still preserve renal, retinal, and macrovascu-
lar health. Changes in LMW-F levels follow changes
in glycemic control and vascular health. Addition-
ally, LMW-F levels can predict levels of inflamma-
tion and oxidative stress. Apart from renal function,
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inflammation and lipids levels are the strongest
predictors of LMW-F levels. The exact chemical
moieties measured by this non-specific fluorescence-
based assay, the relationship between these prod-
ucts and well-defined AGEs and their biological
sources in vivo are not fully elucidated, but studies
are in progress (26). In addition to better biochemi-
cal characterization of the LMW-fluorophores de-
tected by this potentially clinically applicable assay,
longitudinal studies relating these fluorophores to
tissue fluorescence, vascular complications and mor-
tality are warranted. Intervention studies, including
evaluation of effects of AGE inhibitors, AGE break-
ers, antioxidants, and various renal replacement
regimens are also merited.
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